NASDAQ$TARS
Tarsus Pharmaceuticals Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Tarsus' financial performance in Q2 2024 showed significant revenue growth driven by XDEMVY sales, alongside increased operating expenses related to commercialization efforts.
Tarsus Pharmaceuticals reported a strong second quarter in 2024, marked by a 65% increase in revenue compared to Q1 2024, driven by $40.8 million in XDEMVY net product sales. The company saw an improved gross-to-net discount of 44% and delivered over 37,000 bottles of XDEMVY to patients. However, the net loss was $33.3 million, impacted by increased selling, general, and administrative expenses related to the commercial launch of XDEMVY.
- Generated $40.8 million in XDEMVY net product sales, representing a 65% increase over Q1 2024.
- Delivered more than 37,000 bottles of XDEMVY to patients.
- Achieved a gross-to-net discount of 44%, reflecting strong payer coverage.
- Expanded sales force expected to be fully deployed by the end of Q3 2024.
Headline financials
Revenue & EPS history
Tarsus · Revenue · Quarterly
$40.8M
Forward guidance
Tarsus is on track to deploy approximately 50 additional sales force representatives and leaders by the end of Q3 2024 and continuing to advance the pipeline and remain on-track to engage with the FDA on TP-03 (Meibomian Gland Disease), TP-04 (Papulopustular Rosacea) and TP-05 (Lyme disease prevention) by year end 2024
Tailwinds
- On-track to deploy approximately 50 additional sales force representatives and leaders by the end of Q3 2024
- Continuing to advance the pipeline and remain on-track to engage with the FDA on TP-03 (Meibomian Gland Disease)
- Continuing to advance the pipeline and remain on-track to engage with the FDA on TP-04 (Papulopustular Rosacea)
- Continuing to advance the pipeline and remain on-track to engage with the FDA on TP-05 (Lyme disease prevention) by year end 2024
- Remain well positioned for even broader coverage and a steady state gross-to-net discount percentage in the low 40’s in 2025
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+3.2%
Avg return
Earnings day
+4.2%
Avg return
5 days after
+17.8%
Avg return
30 days after
63%
15 / 24 earnings
Positive
+18.3%
Q2 2024
Best reaction
-10.5%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.4% | -8.4% | -9.0% | |
| Q4 2025 | +9.6% | +8.5% | -3.4% | |
| Q3 2025 | -4.7% | +1.8% | +14.4% | |
| Q1 2025 | -6.1% | -5.9% | -14.6% | |
| Q4 2024 | -9.3% | -2.3% | +11.2% | |
| Q3 2024 | -1.9% | -6.2% | +10.4% | |
| Q2 2024 | +18.3% | +16.5% | +34.8% | |
| Q1 2024 | -10.5% | +0.9% | -15.3% | |
| Q4 2023 | +14.2% | +11.4% | +9.6% | |
| Q3 2023 | +5.6% | +8.3% | +4.5% | |
| Q2 2023 | -2.5% | -1.5% | -7.0% | |
| Q1 2023 | +7.1% | +5.8% | +25.9% | |
| Q4 2022 | +0.4% | -10.6% | -15.8% | |
| Q3 2022 | -0.1% | -0.5% | -14.2% | |
| Q2 2022 | +5.4% | +0.6% | -8.3% | |
| Q1 2022 | +7.2% | +16.8% | +25.4% | |
| Q4 2021 | -4.9% | -4.7% | -1.1% | |
| Q3 2021 | +0.4% | -2.9% | -13.8% | |
| Q2 2021 | +6.2% | +3.7% | +13.3% | |
| Q1 2021 | +2.9% | +5.6% | +38.3% | |
| Q4 2020 | +16.4% | +15.8% | +8.6% | |
| Q1 2020 | +7.5% | +16.1% | +111.4% | |
| Q3 2020 | +7.5% | +16.1% | +111.4% | |
| Q2 2020 | +7.5% | +16.1% | +111.4% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro